Pharmaceutical

Regeneron and Mammoth team up to develop gene editing therapies

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.

Apr 27, 2024 - 00:00
Regeneron and Mammoth team up to develop gene editing therapies
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.
Read the original article

Tags:

Previous Article

Multiply Labs and GenScript partner on cell isolation automation

Next Article

AstraZeneca posts $2.18bn profit after tax in Q1 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MHRA fast tracks ADvantage’s immunomodulator for Alzheimer’s disease

MHRA fast tracks ADvantage’s immunomodulator for Alzhei...

Apr 6, 2023

STAT+: How many? One-third of late-stage trials testing multiple sclerosis drugs were never published

STAT+: How many? One-third of late-stage trials testing...

Apr 11, 2023

STAT+: Vinod Khosla predicts AI doctors could be here sooner than you think

STAT+: Vinod Khosla predicts AI doctors could be here s...

May 3, 2023